Investors & Media

Investor Relations

Company Overview

Magenta Therapeutics is a clinical-stage biotechnology company developing therapeutics to revolutionize bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of unmet need, Magenta Therapeutics is pioneering an integrated approach to extend the curative power of bone marrow transplant to more patients by making the process more effective, safer, and easier. Founded by internationally recognized leaders in bone marrow transplant medicine, Magenta Therapeutics was launched in 2016 by Third Rock Ventures and Atlas Venture and is headquartered in Cambridge, Mass.

Media and Investor Contact

For investor and media inquiries, please contact:
Manisha Pai, Vice President of Communications and Investor Relations
investor@magentatx.com

Awards

  • Fierce BiotechFierce Biotech
    Fierce 15 Award
  • Nevy 2017NEVY Award
    Hottest early stage startup
  • Nature BiotechnologyNature Biotech
    Top Academic Spinout 2016